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OBJECTIVES: To calculate direct medical costs of diabetes and its complications for
insulin users from the perspective of the health insurance fund. METHODS: A
6-month, prospective, observational bottom-up cost study of diabetes type 1 and
type 2 for patients on insulin or combined insulin plus oral anti-diabetic therapy
was performed. Data were gathered for anti-diabetic drugs, concomitant medi-
cines, medical devices and hospitalizations, due to diabetes and its complications.
Official drug prices were taken from the positive drug list. All other costs were
gathered from the national framework contract. The annual cost per patient was
calculated for the year 2011 (1.95 BGN 1 EUR). RESULTS: A total of 430 (254 type 2)
patients were included into the study. The total cost per patient per year is BGN
4.500. Out of them, 57% are hospitalization costs due to polyneuropathy, glaucoma,
retinopathy, nephropathy, amputations, and diabetic angiopathy. Anti-diabetic
medicines account for 23% of all costs, medical devices for 4%, and outpatient
treatment of complications and concomitant diseases for 16%. Statistically signif-
icant differences are observed in the cost structure between country regions with
the highest cost per patient in the capital. The percentage of anti-diabetic medi-
cines in the total cost varies depending on the age group: 31% for 20-44 year olds,
29% for 45-59 year olds and 19% for diabetics above 60 years. On the opposite, the
hospitalization cost due to diabetes and its complications is 61% in the oldest age
group while in the youngest is 44%. CONCLUSIONS: Our study confirms that dia-
betes is a costly disease and the majority of the total health care costs relate to
treatment of diabetes complications.
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OBJECTIVES: The Japanese government has recently been promoting home-care.
Local community pharmacies have been playing an important role in home-care,
but virtually no research has been done to clarify the exact nature of their activities.
This study was therefore conducted to elucidate the prescription infrastructure
and home visit activities being conducted by community pharmacies. METHODS:
In March 2012, questionnaires were mailed to community pharmacies in two cities
in Osaka prefecture. The principal items surveyed were the background character-
istics of the patients receiving home visit, the number of pharmacists working at
the pharmacies, and the pharmacies’ facilities/equipment. RESULTS: We received
responses from 90 of the 201 community pharmacies surveyed (response rate:
44.8%). Of these 90 pharmacies, 44 performed home visit. The patients visited at
home were 79.7 years old, on average; 31.8% lived alone, and 22.7% lived with a
spouse, with no children in the home. The responding pharmacies had an average
of 2.2 full-time and 2.5 part-time pharmacists on staff. The mean number of pre-
scriptions filled per day was 80.5, and 91.1% of the pharmacies did not possess
sterile compounding equipment. Of the responding pharmacies, 83.1% stocked
narcotic drugs, and the mean number of narcotics drugs stocked was 8.7. The
parameters that were found to be correlated to the performance of home visit were
the number of full-time pharmacists [p  0.003], the number of narcotic drugs
stocked [p  0.060], and the number of medical instruments/materials possessed
[p  0.057]. CONCLUSIONS: The results show that the patients being visited by
pharmacists are more likely to be elderly living alone who need their drug use
managed by a pharmacist. Most pharmacies conducting home visit do not have
sterile compounding equipment, half of the pharmacists working at these phar-
macies are part-time, and not all of these pharmacies necessarily stock narcotic
drugs.
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OBJECTIVES: To estimate the ICU drug cost impact of clinical pharmacists’ inter-
ventions at the Ghent University Hospital. METHODS: A patient cohort with phar-
macist intervention (I) was compared with a control group (M) (Jan 08 – Dec 11).
Matching criteria were admission year, hospital length of stay (LOS), All Patient
Refined Diagnosis Related Group (APR-DRG), Major Diagnostic Category (MDC),
mortality rate, age. Generic drug names, selected from a pharmacists’ ICU - inter-
vention database were included in the analysis if the cost/daily defined dose
(WHO.int) multiplied with the intervention rate was  50€: acetaminophen, acy-
clovir, ceftazidim, enoxaparin, erythromycin, (es)omeprazole, fluconazole, levo-
floxacin, linezolid, meropenem, piperacillin tazobactam, ranitidin, somatostatin,
teicoplanin, vancomycin, (val)ganciclovir, voriconazole. The average ICU drug cost
was compared between groups and a “drug cost per number of used units” ratio
was calculated: lower ratio for (I) was considered as a more efficient use. (Data are
in % or median with interquartile range IQR; statistical analysis in SPSS, Chi Square
Test; p0.05). RESULTS: Eighty-nine ICU patients receiving intervention were
matched with 167 patients. Median LOS was respectively 39 (22 – 72) days for (I) and
35 (20 – 71) (M). Mortality rate was 29% (both groups). Most prevalent APR-DRG was
septicemia: 16.9% (I); 18.6% (M). Average ICU drug cost was 346.75€ (I) compared to
397.64€ (M) (p0.001); for the selected drugs 168.23€ (I) and 144.52€ (M) (not signif-
icant). Ratios in favour of (I) were found for ceftazidime (p0.001), meropenem
(p0.001), piperacillin tazobactam (p0.001) and teicoplanin (p0.001).
CONCLUSIONS: Average ICU drug cost was lower in a group of patients receiving
pharmacist interventions but this trend could not be attributed to the 19 most
costly and prevalent drugs in intervention. However, for 4 of these drugs data
suggest a more efficient use. This finding needs to be confirmed with prospective
data and to be balanced with health outcomes.
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OBJECTIVES: Many diabetes patients choose to participate in the Ramadan fast
despite medical and religious advice to the contrary. Pharmacists are accessible
health care resources whose guidance can help ensure safe fasting in these indi-
viduals. The aim of this study is to describe Qatar pharmacists’ current practice,
knowledge, and attitudes towards diabetes medication management during
Ramadan.METHODS:A cross-sectional survey was administered to a convenience
sample of 500 pharmacists practicing in Qatar. The 30-item questionnaire was
systematically developed following comprehensive literature review. The volume
and nature of pharmacist interactions with diabetes patients were explored, as
were attitudes regarding pharmacist roles in diabetes care during Ramadan.
Awareness and access of relevant resources was assessed and knowledge of spe-
cific therapeutic and dosing recommendations was evaluated according to the
proposed diabetes medication management and patient risk-assessment strate-
gies endorsed by international medical and religious bodies. RESULTS: The survey
was completed by 166 (33%) pharmacists during May and June 2012. Eighty-eight
(53%) were based in ambulatory care and reported somewhat more interaction (at
least weekly) with diabetes patients during Ramadan than hospital pharmacists
(70.4%, vs. 55.8%, p0.08). Three-quarter of respondents had never read recom-
mended diabetes Ramadan guidelines with 62% using internet resources as their
primary reference to answer fasting-related diabetes questions. Two-thirds of re-
spondents correctly identified how to modify oral diabetes therapy dosing during
Ramadan, but just 20 (12%) did so for insulin. Despite stated barriers of workload,
insufficient access to patient medical records and private counseling areas, phar-
macists overwhelmingly expressed willingness to assume greater roles in diabetes
patient education during Ramadan. CONCLUSIONS: Qatar pharmacists frequently
interact with diabetes patients, but application of recommended medical guide-
lines for care and medication dosing for fasting patients is not optimal. Despite
barriers limiting enhanced participation in diabetes patient management during
Ramadan, pharmacists are interested in developing these services.
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OBJECTIVES: The concept of allocation of research funding in health care depend-
ing on the disease-specific burden to the society was proposed by the governmen-
tal institutions in the USA and Europe. Unfortunately, recent data from the USA
showed that this concept has been unsuccessfully implemented. The objective was
to perform a systematic review of allocation of research funding in health care in
Europe. METHODS: We performed a systematic review of all publications, which
investigated the allocation of research funding in health care of different European
countries in the last 10 years (234 hits). In Germany, we interviewed the main state
funding institutions to acquire data on allocation of funding in national health
care. Data on funding allocation were compared with disability-adjusted life years
(DALY), prevalence and costs of diseases. RESULTS: Data on funding allocation are
not available for the most European countries. Disease burden was inadequately
reflected in those countries where data were available. A comparison between
cancer, coronary heart disease, dementia and stroke, which are among the most
common causes of mortality and disability in Europe, revealed that cancer receives
over 70% of total research funding. Although the health-economic burden of de-
mentia and cancer is similar, dementia receives approximately 10 times less fund-
ing. In the UK, Switzerland and Denmark, cancer receives 49.175€, 25.162€ and
24.424€ of funding per one million of costs. The research funding per one million of
costs is substantially lower in dementia (2.145€ in UK, 11.300€ in Switzerland und
6.808€ in Denmark), and stroke (4.693€, 15.000€ and 11.788€, respectively).
CONCLUSIONS: Disease burden is still inadequately reflected in allocation of re-
search funding in Europe. There is an underfunding of research in brain diseases,
such as stroke and dementia, which are associated with substantial economic
burden. Health-political solutions are necessary to improve the implementation of
the research funding concept.
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OBJECTIVES: To evaluate the utilization of and factors associated with HbA1c test-
ing in the inpatient setting among patients with hyperglycemia. METHODS: Data
were obtained from Humedica’s Integrated Delivery Networks from October 1, 2009
through September 30, 2011. The analyses focused on hospitalization episodes
(admissions and observations) among pre-diabetic/undiagnosed and diabetic pa-
tients with blood glucose values 140 mg/dl, and are descriptive in nature. Results
are statistically significant at the p0.05 level unless otherwise noted. RESULTS: A
total of 55,614 patients contributed to 94,638 unique hospitalization episodes with
at least one occurrence of hyperglycemia. HbA1c tests were performed in 24.6% of
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these hospitalizations, and in 26.4% of patients. Among all hospitalizations, not
having an HbA1c test in the previous 3 months was associated with twice the rate
of those with a previous test (32.4% vs 16.2%), and hospitalizations with glucose
values of 200 mg/dl or greater had a higher rate (27.7%) than did those with lower
glucose levels (18.3%). Endocrinologist treatment during a hospitalization was as-
sociated with a higher HbA1c utilization rate (43.6%) compared to treatment from
all other specialties (23.3%), including hospital medicine (21.1%). Among all pa-
tients, younger patients had a higher HbA1c utilization rate than did patients65
years (47.2% 21, 29.5% 21-64, and 23.8% 65), as did male patients (28.3% vs
24.5%). Type 1 diabetics had a higher rate than did patients with pre-diabetes/
undiagnosed diabetes and type 2 diabetes (32.0%, 28.7%, and 25.4%, respectively).
Among hospitalizations of pre-diabetes/undiagnosed patients who received an
HbA1c test, 17.9% had values of 6.5% or greater.CONCLUSIONS:These data suggest
that overall utilization of HbA1c tests in the hospital setting is low among pre-
diabetic/undiagnosed and diabetic patients with hyperglycemia. The utilization
rate differs significantly by patient characteristics and by physician specialty.
These data highlight the potential to improve identification and diagnosis of dia-
betes within the hospital setting.
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OBJECTIVES: In our earlier cross-sectional analyses of physician involvement in
health care provision for patients with a diagnosis of ADHD (for year 2003), we
observed that only 36% of children and adolescents and 33.5% of adults had been
seen by a CNS specialist. The present study revisits health care provision for ADHD
patients by physician group.METHODS: Patient-level data were extracted for anal-
ysis from the physician-centered claims database of the Kassenaerztliche Vereini-
gung (KV) in Nordbaden / Germany, which covers the entire regional population
enrolled in statutory health insurance (2.2 million lives). For calendar year 2009,
21,287 patients with ADHD [“hyperkinetic disorder”, HKD; ICD-10 codes F90.0 or
F90.1] (male, 15,108; female, 6,179; including 5,931 patients or 27.9% [male, 4,582;
female, 1,349] with coexisting conduct disorder [HKCD; F90.1 or a combination of
F90 and F91]) were available for analysis of health care provider contacts. RESULTS:
Overall, the rate of ADHD patients seen at least once by a CNS specialist (physician)
increased from 42.0% in 2003 to 49.1% in 2009; the rate of those seen at least twice
during the calendar year increased from 26.4% to 33.2% (for age group 0-5 years,
from 9.1% to 11.1%; 6-12 years, from 27.4% to 33.7%, 13-17 years, from 30.3% to
33.1%, 18 years, from 26.4% to 33.2%. Patients with HKCD were more likely to be
seen by CNS specialists than patients with HKD only. Most children (in 2009, 84.4%)
and adolescents (61.0%) were seen at least once by a pediatrician. The rate of
patients seen by psychotherapists remained stable at 10%. Within provider
groups, health care for patients with ADHD was highly concentrated. Each child
and adolescent psychiatrist treated, on average, 231 patients with ADHD.
CONCLUSIONS: Despite a moderate increase since 2003, CNS specialist involve-
ment in health care provision for patients with ADHD remains relatively low.
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OBJECTIVES: To study the rate of suicidality and factors related to the Thai people.
METHODS: Nationally representative face to face household survey based on a
stratified clustered sampling of people aging 15 to 59 (n  17,140). The data were
conducted between June and August 2008 using Mini International Neuropsychi-
atric Interview (M.I.N.I.) module C. Suicidality and general information question-
naire by trained psychiatric professionals. The data analysis was determined by
means adjusted weight of rate generalized to Thai population and analyzed with
descriptive statistical methods by attaining percentage of mean, proportions, stan-
dard errors, population estimation and probability inference from the data.
RESULTS: The overall national rate of suicidality accounted for 7.3%, the severity
risk of suicide was found mild 6.0%, moderate 0.6% and severe 0.7%. The highest
risk of suicide was found in the north (8.8%, severe degree 1.3%) females (8.6%), age
of 35 to 44 (8.1%), separated, divorced or widowed (11.8%), being unemployed
(13.8%), mood disorders with psychotic features (87.9%), current manic episode
(64.3%). CONCLUSIONS: For effective surveillance and prevention of suicide in
Thailand’s population, the focus should be on the population of Northern prov-
inces, females, those in productive age, being unemployed and those concurrently
having mental disorders particulary, mood disorders.
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OBJECTIVES: To evaluate the implementation of National Institute for Health and
Clinical Excellence (NICE) guidance across four hospitals in the NHS South of Eng-
land region, and its impact on patient safety using the following outcome mea-
sures: The percentage of patients for whom a risk assessment was documented;
the percentage of patients who received venous thromboembolism (VTE) prophy-
laxis amongst those who were not risk assessed and the percentage of patients
who received VTE prophylaxis amongst those with a contraindication to VTE
prophylaxis. METHODS: A mixed method approach, which included a retrospec-
tive patient record review of VTE risk assessment documentation and prescribing
of prophylaxis in patients without a risk assessment or a documented contraindi-
cation to VTE prophylaxis prior to and following the implementation of NICE guid-
ance. Qualitative methods in the form of semi-structured interviews were used to
evaluate the implementation strategies employed by the four hospitals. RESULTS:
The percentage of patients for whom a VTE risk assessment was documented
increased from 51.5% (210/408) in 2009 to 79.2% (323/408) in 2010; difference 27.7%
(95% CI: 21.4% to 33.9%; p0.001). There was little evidence of change in the per-
centage who were prescribed prophylaxis amongst patients without a risk assess-
ment (71.7% (142/198) in 2009 and 68.2% (58/85) in 2010; difference -3.5%% (95% CI:
-15.2% to 8.2%; p 0.56) nor the percentage who were prescribed low molecular
weight heparin amongst patients with a contraindication (14% (4/28) in 2009 and
15% (6/41) in 2010; RD 0.3% (95% CI: -16.5% to 17.2%; p0.97).CONCLUSIONS: The
documentation of risk assessment clearly improved following the implementation
of NICE guidance but this did not lead to improved patient safety in terms of
increasing appropriate or decreasing inappropriate prescribing of prophylaxis.
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OBJECTIVES: To develop an off-the-shelf catalogue of quality improvement (QI)
interventions to implement for preventing hospital-acquire pressure ulcers (HA-
PUs). In 2007, the Institute of Healthcare Improvement (IHI) released a 17-item
best-practice framework of general QI interventions organized into four domains
of hospital practice: Leadership; Staff; Information & Information Technology; and
Performance & Improvement. Since HAPU prevention has become a burgeoning
international topic because of its monetary burden on health care, clinicians have
investigated novel methods to bolster HAPU prevention guidelines. QI interven-
tions pose a promising resource for improved HAPU outcomes.METHODS: Starting
with the IHI best-practice framework, fourteen leading experts in QI and HAPU
prevention at academic tertiary care facilities were interviewed in-person to qual-
itatively augment the list of QI interventions to reflect HAPU-specific preventive QI
interventions. The respondents possessed backgrounds as physicians (6), wound
care nurses (4), QI experts (2), and outcomes researchers (2). Interviews followed a
structured outline of the best-practice framework, in which they were allowed to
add, delete or modify QI interventions within each domain as they pertained to
HAPU prevention. RESULTS: The series of qualitative interviews resulted in suc-
cessful augmentation to IHI’s best-practice framework of QI interventions to more
accurately reflect current practice in HAPU prevention. The HAPU-practice frame-
work contains seven Leadership items, six Staff items, four Information & Infor-
mation Technology items, and eight Performance & Improvement items. Of these
items, four were removed from the original framework, twelve were added, and all
remaining items were modified in some manner. CONCLUSIONS: This qualitative
study provides an off-the-shelf catalogue of QI interventions that wound care
teams can utilize for preventing HAPUs and possibly other hospital-acquired con-
ditions. For further consideration, the field would benefit from comparative effec-
tiveness research about QI interventions and strategies for HAPU prevention that
hospitals can then focus their efforts toward.
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OBJECTIVES: We documented the clinical characteristics, treatment patterns, and
resource utilization associated with diverticulitis in a real-world European
population.METHODS:Data were abstracted from medical charts of 1,509 patients
in 5 countries (300 per country): UK, Germany, France, The Netherlands, and
Spain. Inclusion criteria were: diagnosed with diverticulitis during Jnuary 1, 2007–
September 30, 2010; aged 18 years at first (index) diagnosis; no history of colon
cancer; not enrolled in diverticulitis-related clinical trial; and 12 months of chart
history after index diagnosis. Study measures were evaluated over all available
post-index follow-up (12 months). RESULTS: Mean [SD] age at index was 61.7
[11.2] years and 55% of patients were male. Diagnosis setting was evenly distrib-
uted by general practitioner (29%), specialist (24%), emergency (24%), and hospital
(22%). Diabetes was the most common chronic comorbidity (23% of patients) and
20% of patients were considered obese. More than half of patients presented with
or subsequently developed diverticulitis-related complications, most commonly
fissure/abscess/fistula (23%) or lower gastrointestinal (GI) hemorrhage (14%). Peri-
tonitis, a life-threatening infection, was seen in 8.4% of patients. One-fifth (20%)
of patients did not receive antibiotics or other pharmacotherapies (i.e., amin-
osalicylates, analgesics, other GI drugs) used to manage diverticulitis and its symp-
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